Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.

Abstract

Kaposiform hemangioendothelioma is a rare vascular tumor in children. Especially, in association with the Kasabach-Merritt Phenomenon it can be life threatening. The management of these patients is very difficult and an aggressive treatment regime is required. Several multimodality and chemotherapeutic regimens have been described but with variable success and many side effects. We present a 6-week-old boy with Kaposiform hemangioendothelioma and Kasabach-Merritt Phenomenon. Ongoing propranolol treatment with only 4 initial courses of vincristine resulted in a remission that lasted at least 1 year.

• Authors: Denise Josephina Johanna Hermans, Ingrid Mathilde van Beynum, Rozemarijn Junelle van der Vijver, Leonardus Jan Schultze Kool, Ivo de Blaauw, Catharina Joanna Maria van der Vleuten
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 33 Issue 4 Pg. e171-3 (May 2011) ISSN: 1536-3678 [Electronic] United States
• PMID: 21516018 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Antineoplastic Agents, Phytogenic
• Vincristine
• Propranolol

Topics

• Adrenergic beta-Antagonists (administration & dosage)
• Antineoplastic Agents, Phytogenic (administration & dosage)
• Disseminated Intravascular Coagulation (drug therapy, etiology)
• Drug Therapy, Combination
• Hemangioendothelioma (complications, drug therapy)
• Hemangioma, Capillary (drug therapy, etiology)
• Hemangioma, Cavernous (complications, drug therapy)
• Humans
• Infant
• Kasabach-Merritt Syndrome
• Male
• Propranolol (administration & dosage)
• Remission Induction
• Sarcoma, Kaposi (complications, drug therapy)
• Skin Neoplasms (complications, drug therapy)
• Thrombocytopenia (complications, drug therapy)
• Vascular Neoplasms (complications, drug therapy)
• Vincristine (administration & dosage)